scholarly journals Hyperlipidemia Condition and Novel-Drug Therapies: A Overall Study

2021 ◽  
pp. 171-186
Author(s):  
CH. K. V. L. S. N. Anjana Male ◽  
V. Swathi ◽  
D. Sai Kumar ◽  
. Karishma ◽  
Md. Shuaib Yunus
Keyword(s):  
Diabetes Mellitus ◽  
Energy Use ◽  
Climatic Factors ◽  
Saturated Fat ◽  
Egg Yolk ◽  
Cholesterol Absorption ◽  
Hormone Production ◽  
Bile Acid Sequestrants ◽  
First Line Therapy ◽  
Obesity And Diabetes

Hyperlipidaemia is an condition that increases the chance of coronary heart disease (CHD) and atherosclerotic disease (ASHD) in blood vessels. Hyperlipidaemia occurs in response to smoking, obesity, sedentary lifestyle, and other risk factors to extend CHD. Cardiovascular disease (CVD) is the reason for death. Hyperlipidaemia is divided into two broad classifications: Primary (familial) and Secondary (acquired). Primary hyperlipidemia has been generated by hereditary defects and climatic factors or by undisclosed mechanisms. Secondary hyperlipidemia concern to the metabolic disorders linked with the diabetes mellitus, liver complication, thyroid, and kidney complications. Hyperlipidemia also refers to as elevated levels of lipids within the blood. Circulating lipid are carried in lipoproteins that transport the lipids to varied tissues for energy use, lipid deposition, hormone production, and steroid formation. The lipoprotein consists of esterified and unesterified cholesterol, triglycerides, phospholipids, and protein. The general public who have hyperlipidemia experience no symptoms. Hyperlipidemia is most oftenly correlated with high-fat diets, a stationary lifestyle, obesity and diabetes mellitus. Four different classes of cholesterol-lowering drugs namely, statins, niacin, resins, and fibrates are available to treat hyperlipidemia; however, statins are now considered to be the first line therapy. The preventable causes of hyperlipidemia can include: Smoking, Being overweight, Physical inactivity, Steroid use, Alcohol consumption & Diet high in saturated fat, & cholesterol such as cheese, meat, fried & processed foods and egg yolk. The treatment of hyperlipidemia includes statins, bile acid sequestrants, fibric acids, niacin, and cholesterol absorption inhibitors. There are some of the novel drugs which are selected for the treatment of hyperlipidemia which includes: Evolocumab, Alirocumab, Bempedoic acid, Lomitapide, Evinacumab, and Sebelipase alfa.

scholarly journals Statin use and risk of diabetes mellitus

2012 ◽  
Vol 15 (2) ◽  
pp. 77-82
Author(s):  
Oksana Mikhailovna Drapkina ◽  
Marina Viktorovna Kostyukevich
Keyword(s):  
Diabetes Mellitus ◽  
Combined Treatment ◽  
Risk Groups ◽  
First Line ◽  
Bile Acid Sequestrants ◽  
First Line Therapy ◽  
Line Therapy ◽  
Increased Risk ◽  
Increase Risk

At present time four groups of medications are used to correct dyslipidemia: bile acid sequestrants, niacin, fibric acid derivatives andstatins. During last years statins' potential to increase risk of type 2 diabetes mellitus (T2DM) is actively discussed, though no commonopinion about the possible mechanism of such effect has evolved as yet. Insulin desensitizing effect as a class feature of statins remainsa disputable question.Position of statins as a first-line therapy for severe hyperlipidemia seems undoubted; however they do not improve insulin sensitivity.Moreover, several studies reported increased risk of T2DM. It is feasible to consider combined treatment (including metformin) inpatients from risk groups for development of T2DM, receiving statins

The Effect of Probiotics Supplementation in Maternal-Fetal Care

2020 ◽  
Vol 16 ◽  
Author(s):  
Mahnaz Mardani ◽  
Sadegh Rezapour
Keyword(s):  
Diabetes Mellitus ◽  
Protective Role ◽  
Optimum Dose ◽  
Active Living ◽  
Maternal Weight Gain ◽  
Long Term Effects ◽  
Maternal Weight ◽  
Human Gut ◽  
Obesity And Diabetes

: Pregnancy-related complications can have long-term effects on mother and fetus/child. Microbiome within the human gut is an important factor to maintain optimum health during pregnancy and could possibly reduce the incidence of these complications. Probiotics are active living microorganisms that can provide the host with health benefits such as; immune and hormonal regulatory and metabolic benefits when administered in adequate and optimum dose. Probiotic supplementations also regulate abnormal and unbalanced microflora population that can control the pathogenesis of several diseases like obesity and diabetes. Probiotics also play a protective role in complications like preeclampsia, gestational diabetes mellitus and maternal weight gain and enhance successful outcomes of reproduction. This mini review will thereby summarize the maternal and fetal effects of probiotics during pregnancy.

SGLT-2 inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.

2020 ◽  
Vol 13 ◽  
Author(s):  
Keshav Kumar ◽  
Tapan Behl ◽  
Arun Kumar ◽  
Sandeep Arora
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Transporter ◽  
Clinical Trial Data ◽  
Cardiac Complications ◽  
Cardiac Inflammation ◽  
First Line Therapy ◽  
Glucose Transporter 2 ◽  
Specific Medication ◽  
Hba1c Levels

Background: A chronic metabolic disease, diabetes mellitus (DM), is associated with various comorbidity due to cardiac complications that considerably decreasing the quality of life, but there is no specific medication for this. The recent developed drugs Sodium glucose transporter 2 inhibitors (SGLT2-Is), have action on diabetes as well as on kidney. Current research and studies have shown that SGLT2-Is attenuated the risk of cardiac complication associated with morbidity and hospitalization in diabetes patients. Introduction: Sodium glucose linked transporter 2 (SGLT2) receptors are mainly situated in proximal tubule of nephron. About 90% of glucose concentration is reabsorbed by these receptors in the nephron. The advanced remedy for the management of DM is SGLT2-Is which inhibit or lower the reabsorption of glucose. Objectives: The present review explores the mechanistic principle and the clinical trial data of SGLT2-Is which further support cardioprotective effects associated with these medications. Methods: The review collaborates PUBMED, Google Scholar and Research gate databases, which were explored using keywords and their combinations such as sodium glucose co-transporter 2 inhibitors, diabetes mellitus, cardioprotective effect, empagliflozin, canagliflozin, dapagliflozin and several others, to create an eclectic manuscript. Results: SGLT2-Is showed improvement in diabetes as well as in cardiac complications. These medications decreased HbA1c levels to control hyperglycemia. The mechanism of action of these drugs showed reduction in cardiac oxidative stress, cardiac apoptosis and cardiac inflammation. Besides, SGLT-2-Is showed improvement in cardiac structure and cardiac function. Conclusion: Anti-diabetic drugs, SGLT2-Is have a protective effect against cardiac complications. This indicates that these medication could become first line therapy for cardiac patients with DM.

scholarly journals Mini-Gastric Bypass to Control Morbid Obesity and Diabetes Mellitus: What Radiologists Need to Know

2015 ◽  
Vol 16 (2) ◽  
pp. 325 ◽  
Author(s):  
Hyun Jeong Park ◽  
Seong Sook Hong ◽  
Jiyoung Hwang ◽  
Kyung Yul Hur
Keyword(s):  
Diabetes Mellitus ◽  
Morbid Obesity ◽  
Gastric Bypass ◽  
Mini Gastric Bypass ◽  
Obesity And Diabetes

Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications

2013 ◽  
Vol 126 (7) ◽  
pp. 471-482 ◽  
Author(s):  
Vaibhav B. Patel ◽  
Nirmal Parajuli ◽  
Gavin Y. Oudit
Keyword(s):  
Diabetes Mellitus ◽  
Angiotensin Converting Enzyme ◽  
Vascular Function ◽  
Systolic Dysfunction ◽  
Cardiovascular Complications ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Obesity And Diabetes

Diabetes mellitus results in severe cardiovascular complications, and heart disease and failure remain the major causes of death in patients with diabetes. Given the increasing global tide of obesity and diabetes, the clinical burden of diabetes-induced cardiovascular disease is reaching epidemic proportions. Therefore urgent actions are needed to stem the tide of diabetes which entails new prevention and treatment tools. Clinical and pharmacological studies have demonstrated that AngII (angiotensin II), the major effector peptide of the RAS (renin–angiotensin system), is a critical promoter of insulin resistance and diabetes mellitus. The role of RAS and AngII has been implicated in the progression of diabetic cardiovascular complications and AT1R (AngII type 1 receptor) blockers and ACE (angiotensin-converting enzyme) inhibitors have shown clinical benefits. ACE2, the recently discovered homologue of ACE, is a monocarboxypeptidase which converts AngII into Ang-(1–7) [angiotensin-(1–7)] which, by virtue of its actions on the MasR (Mas receptor), opposes the effects of AngII. In animal models of diabetes, an early increase in ACE2 expression and activity occurs, whereas ACE2 mRNA and protein levels have been found to decrease in older STZ (streptozotocin)-induced diabetic rats. Using the Akita mouse model of Type 1 diabetes, we have recently shown that loss of ACE2 disrupts the balance of the RAS in a diabetic state and leads to AngII/AT1R-dependent systolic dysfunction and impaired vascular function. In the present review, we will discuss the role of the RAS in the pathophysiology and treatment of diabetes and its complications with particular emphasis on potential benefits of the ACE2/Ang-(1–7)/MasR axis activation.

scholarly journals Obesity and Diabetes Mellitus as Predictors of Mortality in Patients with Stroke: A Meta Analysis

2019 ◽  
Vol 4 (4) ◽  
pp. 383-393
Author(s):  
Karlinda Karlinda ◽  
◽  
Didik Gunawan Tamtomo ◽  
Bhisma Murti ◽  
◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Meta Analysis ◽  
Predictors Of Mortality ◽  
Obesity And Diabetes

scholarly journals The Effect of Green Space on the Physiologic Function of the Adult: A Systematic Review

2021 ◽  
Author(s):  
Brenna Franco
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Cohort Studies ◽  
Protective Factor ◽  
Green Space ◽  
Inclusion Criteria ◽  
Disease Awareness ◽  
Obesity And Diabetes ◽  
Physiologic Function ◽  
Cardiovascular Illness

Environmental greenness is often associated with improved psychological outcomes, but the use of green space as a protective factor for maintaining physiologic health is understudied. However, growing evidence exists on the benefit of greenness on physiologic health. The purpose of this systematic review was to evaluate the effect of green space on the physiologic function of the adult. Cohort studies were searched for that had all elements of inclusion criteria. Six final studies were included in this systematic review utilizing PRISMA guidelines and CASP tool for cohort studies. Data from the studies was collected and a cross study analysis was conducted to compare all studies and assess for themes in study outcomes. Results of this review demonstrate that green space has a protective effect on physiologic health. Areas with higher levels of greenness are associated with lower prevalence of central obesity, diabetes mellitus, and self-reported rates of cardiovascular disease and stroke as well as decreased rates of mortality from cancers, and kidney and respiratory diseases. Implications of this study include the importance in understanding risk factors for development of disease. Awareness of a patient’s environment that includes natural spaces should be identified as a potential risk factor for the development of cardiovascular illness, obesity, and diabetes mellitus.

scholarly journals Gestational microbiome: metabolic perturbations and developmental programming

Reproduction ◽  
2021 ◽  
Vol 162 (6) ◽  
pp. R85-R98
Author(s):  
Sophia Han ◽  
Charlotte C Ellberg ◽  
Isoken N Olomu ◽  
Arpita K Vyas
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Human Microbiome ◽  
Disease States ◽  
Microbial Dysbiosis ◽  
Obesity And Diabetes ◽  
Growing Body

A growing body of research suggests that alterations to the human microbiome are associated with disease states, including obesity and diabetes. During pregnancy, these disease states are associated with maternal microbial dysbiosis. This review discusses the current literature regarding the typical maternal and offspring microbiome as well as alterations to the microbiome in the context of obesity, type 2 diabetes mellitus, and gestational diabetes mellitus. Furthermore, this review outlines the proposed mechanisms linking associations between the maternal microbiome in the aforementioned disease states and offspring microbiome. Additionally, this review highlights associations between alterations in offspring microbiome and postnatal health outcomes.

scholarly journals Docking protein 1 and free fatty acids are associated with insulin resistance in patients with type 2 diabetes mellitus

2021 ◽  
Vol 49 (11) ◽  
pp. 030006052110482
Author(s):  
Xiaoqin Ha ◽  
Xiaoling Cai ◽  
Huizhe Cao ◽  
Jie Li ◽  
Bo Yang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Effective Means ◽  
Model Assessment ◽  
High Concentration ◽  
Obesity And Diabetes ◽  
Docking Protein

Objective Insulin resistance (IR) is a key defect in type 2 diabetes mellitus (T2DM); therefore, effective means of ameliorating IR are sought. Methods We performed a retrospective cohort study of 154 patients with T2DM and 39 with pre-diabetes (pre-DM). The effects of IR and a high concentration of FFA on gene expression were determined using microarray analysis and quantitative reverse transcription polymerase chain reaction (RT-qPCR) in patients with T2DM or pre-DM. Results Serum FFA concentration and homeostasis model assessment of IR (HOMA-IR) were significantly higher in patients with T2DM but no obesity and in those with pre-DM than in controls. HOMA-IR was significantly associated with T2DM. RT-qPCR showed that the expression of FBJ murine osteosarcoma viral oncogene homolog ( FOS) and AE binding protein 1 ( AEBP1) was much lower in the circulation of participants with obesity and diabetes. RT-qPCR showed that the expression of docking protein 1 ( DOK1) was significantly lower in the blood of participants with diabetes but no obesity and in those with pre-DM than in controls. Conclusions FFA and DOK1 are associated with IR in patients with T2DM but no obesity or pre-DM. The downregulation of DOK1 might inhibit lipid synthesis and induce lipolysis, inducing or worsening IR.

Sign in / Sign up

Export Citation Format

Share Document